Free Trial
NASDAQ:ZBIO

Zenas Biopharma (ZBIO) Stock Price, News & Analysis

Zenas Biopharma logo
$11.45 +0.51 (+4.66%)
As of 04:00 PM Eastern

About Zenas Biopharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$10.67
$11.66
50-Day Range
$6.77
$11.92
52-Week Range
$5.83
$26.25
Volume
85,438 shs
Average Volume
183,330 shs
Market Capitalization
$479.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.67
Consensus Rating
Buy

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas Biopharma's stock was trading at $7.90 at the beginning of 2025. Since then, ZBIO shares have increased by 44.9% and is now trading at $11.45.
View the best growth stocks for 2025 here
.

Zenas Biopharma Inc (NASDAQ:ZBIO) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.35. The company earned $10 million during the quarter, compared to analysts' expectations of $5 million.

Zenas Biopharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

Zenas Biopharma's top institutional shareholders include Wellington Management Group LLP (2.09%), Charles Schwab Investment Management Inc. (0.28%), Jefferies Financial Group Inc. (0.11%) and Nuveen LLC (0.08%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

Last Earnings
5/15/2025
Today
5/22/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.67
High Stock Price Target
$45.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+216.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$484.86 million
Optionable
N/A
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners